Correlation of ctDNA and response in patients (pts) with PDGFRα D842 GIST treated with avapritinib
Year: 2018
Type: article
Abstract: Background: Avapritinib (ava) is a potent and selective inhibitor of activated KIT and PDGFRA, which has shown broad activity against GIST in pts in the Phase 1 NAVIGATOR study (NCT02508532), particularly in those with PDGFRα D842 mutations. We investigated whether baseline ctDNA levels and changes in ctDNA during treatment were associated with response.
Source: Annals of Oncology
Institutions: Dana-Farber Cancer Institute, Essen University Hospital, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital, Vall d'Hebron Institute of Oncology, Fox Chase Cancer Center, Asan Medical Center, Universitair Ziekenhuis Leuven, Centre Léon Bérard, Erasmus MC Cancer Institute, Institut Gustave Roussy, Fondation Gustave Roussy, Memorial Sloan Kettering Cancer Center, Sarcoma Oncology Center, The Maria Sklodowska-Curie National Research Institute of Oncology, Blueprint Medicines (United States), OHSU Knight Cancer Institute
Language: English
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2897467476